0000950170-24-034708.txt : 20240321 0000950170-24-034708.hdr.sgml : 20240321 20240321161513 ACCESSION NUMBER: 0000950170-24-034708 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20240320 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240321 DATE AS OF CHANGE: 20240321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evoke Pharma Inc CENTRAL INDEX KEY: 0001403708 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 208447886 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36075 FILM NUMBER: 24771530 BUSINESS ADDRESS: STREET 1: 420 STEVENS AVENUE STREET 2: SUITE 370 CITY: SOLANA BEACH STATE: CA ZIP: 92075 BUSINESS PHONE: 858-345-1494 MAIL ADDRESS: STREET 1: 420 STEVENS AVENUE STREET 2: SUITE 370 CITY: SOLANA BEACH STATE: CA ZIP: 92075 8-K 1 evok-20240320.htm 8-K 8-K
false000140370800014037082024-03-202024-03-20

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 20, 2024

 

 

EVOKE PHARMA, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-36075

20-8447886

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

420 Stevens Avenue, Suite 230

 

Solana Beach, California

 

92075

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 858 345-1494

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

EVOK

 

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 20, 2024, the board of directors (the “Board’) of Evoke Pharma, Inc. (the “Company”) appointed Matthew J. D’Onofrio as the Company’s Chief Executive Officer, effective as of March 31, 2024. Mr. D’Onofrio will succeed Dave A. Gonyer, R. Ph., the Company’s current Chief Executive Officer, who is resigning effective as of March 31, 2024, for personal reasons. Mr. Gonyer’s departure is not due to any disagreement with the Company or on any matter related to the Company’s operations, policies, or practices. Mr. Gonyer has also resigned as a member of the Board and Mr. D’Onofrio was appointed as a member of the Board, in each case, effective as of March 31, 2024.

Mr. D’Onofrio is one the Company’s co-founders and has served as our President, Chief Operating Officer, Secretary and Treasurer since February 2023 and in prior executive positions at the Company since March 2007. The full biography and other information with respect to Mr. D’Onofrio required by Item 5.02(c) of Form 8-K are included in the Company’s proxy statement on Schedule 14A for the 2023 annual meeting of stockholders filed with the SEC on March 29, 2023 under the heading “Executive Compensation and Other Information” and such biography and information are incorporated herein by reference. There are no family relationships between Mr. D’Onofrio and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

EVOKE PHARMA, INC.

 

 

 

 

Date:

March 21, 2024

By:

/s/ Matthew J. D'Onofrio

 

 

 

Name: Matthew J. D'Onofrio
Title: President, Chief Operating Officer and Secretary

 

 EX-101.SCH 2 evok-20240320.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 4 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Document And Entity Information
Mar. 20, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 20, 2024
Entity Registrant Name EVOKE PHARMA, INC.
Entity Central Index Key 0001403708
Entity Emerging Growth Company false
Entity File Number 001-36075
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-8447886
Entity Address, Address Line One 420 Stevens Avenue, Suite 230
Entity Address, City or Town Solana Beach
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92075
City Area Code 858
Local Phone Number 345-1494
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol EVOK
Security Exchange Name NASDAQ
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( .2!=5@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #D@758"=*Q"N\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>.FD'AZCK96BG(2$Q"<0M2KPMHFFCQ*C=VY.&K1."!^ 8^\_G MSY(;[:4> CZ'P6,@B_%NN@9N@!E&&%S\+J!9B+GZ)S9W@%V24[1+:AS'=QO65OQ:E7PNJC$ON)2W$N^>I]=?_C=A-U@[,'^ M8^.K8-O K[MHOP!02P,$% @ Y(%U6)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #D@758/M4X_6($ "Y$ & 'AL+W=OFT,TG\@'E("LPX).DQN21<2.]FVND+80NLB6WY)!F2 M;]^5 9NF9LU,7P0LH_W[I]5Z=Y7A1LA7%3.FR5N:9&IDQ5KG5[:MPIBE5%V( MG&7PRU+(E&H8RI6MTY3L].*<^L\;"\-Y/CH2ATPC,VDT05:4KE M^S5+Q&9DN=;^QC-?Q=K(B(Y(M1U;@7EU[ MOC$H9WSC;*,.KHE9RD*(5S.81B/+,40L8:$V$A2^UFS"DL0H <>/G:A5/=,8 M'E[OU>_*Q<-B%E2QB4B^\TC'(VM@D8@M:9'H9['YS'8+ZAJ]4"2J_"2;[5S? MMTA8*"W2G3$0I#S;?M.WG2,.#;PC!M[.P"NYMP\J*6^HIN.A%!LBS6Q0,Q?E M4DMK@..9V96YEO K!SL]OA%A 4[6),@BX2NFJBP.V7-%$,X>A6'-W3G#%CD@L34!&!L&ST"ZY4A5%; M'/4JM!XJN(OM9[;B)I* \9&FC6 M.M^>[F_)['/P_!"GCY *!ZU=P_5/@ M)N Z21-X 2/V1N[9>Q,>KN0XCNL[G;XS0+ &%=;@%*S;E,D5SU;D=[#7,9F( M-*=9(QRNUQ9FEQ77Y2E<=SQAY+%(%TPVL> :X*?S3L_I=Q$>UZFSJ',*T30+ MA>0I:_8=+NE[#NP# M6T,C00+X+!CL2\%A7[R.@T'7!<#%4_A'Z(D9P::_B$US_<3EYB*A&277C(8Q MQE?7!A=/[A_YJJB<2;'F6=CL55QS$F!H=;EP\2S_$6TFE(;\]R?/C[\JN.*E MU_)*U_7"Q1-]N8T!=+K'45"!YKZ##+I89G;KBN'BB?Z+",%3LUAD6 YL$>GX MW7/7O\3JJUL7"Q?/[M\EUYIEICRD1;9++:J1ZO^5";>N$RZ>Y.%=XB'7IG8] M0-!+3I-&'EREC<>KRX2')_*99."+_#]E4J0+(6@%QV5; @V, GL=?N(9J+Y;$]7Y9_$KF+"P@WAJ;D!8E$Y]0 M\^9:A*]G)*>2K&E2,/+)N3#=$\EAO2JF$N6NJX.'I_,722,3?_/W="$:HZ]% MP#2<&$E=!SP\9^]=1F[?PIAF*W:T VX1>@SF-\'7)B;[X"!J#O70Q4/CJ$C" MEJ#D7/0A>&D6U[&C$+$F0GP^U((O1^8XV[UWXKQ/U!+ M P04 " #D@758GZ ;\+$" #B# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67=A['- MHN6/O.-%Q[I#)6,>=5 M6R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0G MCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L, M/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(! M6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@ M?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\ M@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T M7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIU MTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G' M!QR>(W?#$T%^@2O&+(= M/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@ M/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G& MD3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2='@//GL? M)=-[*CG_5U/\!%!+ P04 " #D@758EXJ[', 3 @ "P %]R96QS M+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0 M"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-# ML%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H M5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( .2!=5@ZJJ+G0 $ #P" / M >&PO=V]R:V)O;VLN>&ULC5%=:\,P#/PKQC]@20SH\0RVT+E6J:'3"T4\4V#C-E4DYPH]&09;B(S5 M'WC3B?PT9>H1-N6'$2&%GN5"6&-,W&_T_$8T'D&6A^[ ](2.(2X-PW.D0XMA MU]&(B^S"1I_#6(<0Y_$_,5)=8P5+J@X> @\Y1G"=P) :;)-6P7@H]+BB[H-5 MCX$E)+4* Y7L=D[E],H.KEGD7F08YRB#N+*#\%&MA1H#V#:;7-Y-;2>C@W(-@[^&5C!W-CQ]W]P-02P,$% @ Y(%U6"0>FZ*M M^ $ !H !X;"]?+7_OR4Z?:!1W;J"V\R1& M:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T M==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+) M(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( .2!=5AED'F2 M&0$ ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N M+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78 ME!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')O MJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1< M^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!G MZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%. M6X.^D&PO=&AE;64O=&AE M;64Q+GAM;%!+ 0(4 Q0 ( .2!=5@^U3C]8@0 +D0 8 M " @0X( !X;"]W;W)K&PO&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'-02P$"% ,4 " #D@75899!YDAD! #/ P $P M @ &]$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" ( '% ! end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports evok-20240320.htm evok-20240320.xsd http://xbrl.sec.gov/dei/2023 false false JSON 11 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "evok-20240320.htm": { "nsprefix": "evok", "nsuri": "http://www.evokepharma.com/20240320", "dts": { "inline": { "local": [ "evok-20240320.htm" ] }, "schema": { "local": [ "evok-20240320.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_c6611154-e8ce-4a33-ac8c-4c84b792dfec", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "evok-20240320.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6611154-e8ce-4a33-ac8c-4c84b792dfec", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "evok-20240320.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.evokepharma.com/20240320/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 12 0000950170-24-034708-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-034708-xbrl.zip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end XML 14 evok-20240320_htm.xml IDEA: XBRL DOCUMENT 0001403708 2024-03-20 2024-03-20 false 0001403708 8-K 2024-03-20 EVOKE PHARMA, INC. DE 001-36075 20-8447886 420 Stevens Avenue, Suite 230 Solana Beach CA 92075 858 345-1494 false false false false Common Stock, par value $0.0001 per share EVOK NASDAQ false